Treadwell Therapeutics is a clinical-stage oncology company exploiting cancer cells’ vulnerabilities to develop first-in-class and best-in-class small molecules to address unmet needs in patients with highly aggressive cancers.
Treadwell Therapeutics is developing a novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities including aneuploidy and immunogenicity.
Treadwell Therapeutics was founded in 2019 and is headquartered in New York, New York.
Treadwell Therapeutics' robust, internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945 and a potentially best-in-class TTK inhibitor, CFI-402257 ready for Phase 2, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1, which will enter the clinic in early 2020.
Treadwell Therapeutics has raised $27M in a Seed round on Jan 13, 2020. The financing is backed by TIO Bioventures.